18 research outputs found
The global, regional, and national burden of adult lip, oral, and pharyngeal cancer in 204 countries and territories:A systematic analysis for the Global Burden of Disease Study 2019
Importance Lip, oral, and pharyngeal cancers are important contributors to cancer burden worldwide, and a comprehensive evaluation of their burden globally, regionally, and nationally is crucial for effective policy planning.Objective To analyze the total and risk-attributable burden of lip and oral cavity cancer (LOC) and other pharyngeal cancer (OPC) for 204 countries and territories and by Socio-demographic Index (SDI) using 2019 Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study estimates.Evidence Review The incidence, mortality, and disability-adjusted life years (DALYs) due to LOC and OPC from 1990 to 2019 were estimated using GBD 2019 methods. The GBD 2019 comparative risk assessment framework was used to estimate the proportion of deaths and DALYs for LOC and OPC attributable to smoking, tobacco, and alcohol consumption in 2019.Findings In 2019, 370 000 (95% uncertainty interval [UI], 338 000-401 000) cases and 199 000 (95% UI, 181 000-217 000) deaths for LOC and 167 000 (95% UI, 153 000-180 000) cases and 114 000 (95% UI, 103 000-126 000) deaths for OPC were estimated to occur globally, contributing 5.5 million (95% UI, 5.0-6.0 million) and 3.2 million (95% UI, 2.9-3.6 million) DALYs, respectively. From 1990 to 2019, low-middle and low SDI regions consistently showed the highest age-standardized mortality rates due to LOC and OPC, while the high SDI strata exhibited age-standardized incidence rates decreasing for LOC and increasing for OPC. Globally in 2019, smoking had the greatest contribution to risk-attributable OPC deaths for both sexes (55.8% [95% UI, 49.2%-62.0%] of all OPC deaths in male individuals and 17.4% [95% UI, 13.8%-21.2%] of all OPC deaths in female individuals). Smoking and alcohol both contributed to substantial LOC deaths globally among male individuals (42.3% [95% UI, 35.2%-48.6%] and 40.2% [95% UI, 33.3%-46.8%] of all risk-attributable cancer deaths, respectively), while chewing tobacco contributed to the greatest attributable LOC deaths among female individuals (27.6% [95% UI, 21.5%-33.8%]), driven by high risk-attributable burden in South and Southeast Asia.Conclusions and Relevance In this systematic analysis, disparities in LOC and OPC burden existed across the SDI spectrum, and a considerable percentage of burden was attributable to tobacco and alcohol use. These estimates can contribute to an understanding of the distribution and disparities in LOC and OPC burden globally and support cancer control planning efforts
The global burden of adolescent and young adult cancer in 2019 : a systematic analysis for the Global Burden of Disease Study 2019
Background In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in adolescents and young adults (aged 15-39 years) are lacking. To address this gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents and young adults. Methods Using the GBD 2019 methodology, international mortality data were collected from vital registration systems, verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index (SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15-39 years to define adolescents and young adults. Findings There were 1.19 million (95% UI 1.11-1.28) incident cancer cases and 396 000 (370 000-425 000) deaths due to cancer among people aged 15-39 years worldwide in 2019. The highest age-standardised incidence rates occurred in high SDI (59.6 [54.5-65.7] per 100 000 person-years) and high-middle SDI countries (53.2 [48.8-57.9] per 100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14.2 [12.9-15.6] per 100 000 person-years) and middle SDI (13.6 [12.6-14.8] per 100 000 person-years) countries. In 2019, adolescent and young adult cancers contributed 23.5 million (21.9-25.2) DALYs to the global burden of disease, of which 2.7% (1.9-3.6) came from YLDs and 97.3% (96.4-98.1) from YLLs. Cancer was the fourth leading cause of death and tenth leading cause of DALYs in adolescents and young adults globally. Interpretation Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, these estimates can inform global and country-level cancer control efforts. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe
The global burden of cancer attributable to risk factors, 2010-19 : a systematic analysis for the Global Burden of Disease Study 2019
Background Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. Findings Globally, in 2019, the risk factors included in this analysis accounted for 4.45 million (95% uncertainty interval 4.01-4.94) deaths and 105 million (95.0-116) DALYs for both sexes combined, representing 44.4% (41.3-48.4) of all cancer deaths and 42.0% (39.1-45.6) of all DALYs. There were 2.88 million (2.60-3.18) risk-attributable cancer deaths in males (50.6% [47.8-54.1] of all male cancer deaths) and 1.58 million (1.36-1.84) risk-attributable cancer deaths in females (36.3% [32.5-41.3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20.4% (12.6-28.4) and DALYs by 16.8% (8.8-25.0), with the greatest percentage increase in metabolic risks (34.7% [27.9-42.8] and 33.3% [25.8-42.0]). Interpretation The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.Peer reviewe
Interferon gamma release assay, a powerful tool for the detection of human and bovine tuberculosis in the greater Cairo area compared to other diagnostic tools
Rapid detection is essential for the elimination and control of tuberculosis (TB) worldwide. Our study aimed to
show the current and actual patterns of human and bovine TB distribution in the Greater Cairo Area community by the
application of different TB diagnostic tools to individuals and farm animals with suspected TB. Both sputum and blood
specimens were collected from 150 suspected human cases in the community. Sputum samples were examined using
direct microscopy (Ziehl-Neelsen stain), culture on Lowenstein-Jensen medium, and real-time PCR. Blood samples
were used for interferon gamma release assay (IGRA). In addition, lymph nodes and blood samples were collected from
57 tuberculin-positive animals. Lymph nodes were examined using direct microscopy (Ziehl-Neelsen stain), culture
on Lowenstein-Jensen medium, and real-time PCR. Animal blood samples were also tested with IGRA. Sensitivity
and specificity as well as positive and negative predictive values were calculated for all tests. The results showed that
for both human and animal samples, IGRA provided the most accurate estimates of current TB infection compared
to other tests. Furthermore, IGRA had the highest sensitivity and was the most convenient, proving its superiority
compared to traditional methods in showing true levels of TB dissemination. This work shows that IGRA is a powerful
tool for detection of TB in suspected humans and farm animals and should be incorporated into routine TB screening
programs, which require more than one test
Major Gram-negative bacterial causes isolated from apparent Healthy and diarrheic foals in Egypt, prevalence, identification and antibiotic susceptibility profiles
Diarrhea is one of the most significant illnesses affecting young foals and may be manifested in more than half of foals up to 3 months of age. Numerous infectious causes have been involved but bacterial pathogens are concerned. This study aimed to assess and identify the prime Gram-negative bacteriological etiology of Arabian horse foals’ diarrhea in Egypt and to designate the antibiotic susceptibility profiles of the isolated microorganisms.  Rectal swabs and internal organs were obtained from 216 foals (89 diarrheic and 127 apparently healthy), aged 1 week to 1 year old, reared in Arabian horse farms in Great Cairo, Egypt during a period extended from March 2022 to December 2022. Conventional bacteriological examination was performed using selective media persuaded by routine and advanced biochemical tests. The isolation displayed 648 bacterial isolates; 452 (68.6%) were Gram-negative with the mixed isolation representing about 28%. Escherichia coli constituted the most prevalent; 110 / 452 (24.34%); 65 in apparently healthy foals and 45 among diarrheic ones. The second was Klebsiella pneumoniae (72, 15.92%) at which 50, (15.67%) were found to expose the highest causative agent recovered from diarrheic foals. Imipenem, quinolones, and trimethoprim/sulfamethoxazole were the most effective versus Gram-negative species isolated from diarrheic foals while ampicillin and tetracycline were of no effect. The phenotypic antibiotic susceptibility test revealed a picture of multidrug resistance (MDR) as 111 isolates (28.71%) showed resistance to three or more antibiotics belonging to different groups. The results demonstrated that Klebsiella pneumonia was the highest MDR species (54.16%) followed by Pseudomonas aeruginosa, Salmonella enterica, and Escherichia coli isolates by 43.9, 32.1 and 30.9 % respectively. In conclusion, Gram-negative bacteria constituted the major causative agents of diarrhea in the Arabian foals. The most effective antibacterial drugs were imipenem, quinolones, and trimethoprim/ sulfamethoxazole. The issue of the existence of multidrug resistance isolates should be considered for proper therapy of foal diarrhea
Major Gram-negative bacterial causes isolated from apparent Healthy and diarrheic foals in Egypt, prevalence, identification and antibiotic susceptibility profiles
Diarrhea is one of the most significant illnesses affecting young foals and may be manifested in more than half of foals up to 3 months of age. Numerous infectious causes have been involved but bacterial pathogens are concerned. This study aimed to assess and identify the prime Gram-negative bacteriological etiology of Arabian horse foals’ diarrhea in Egypt and to designate the antibiotic susceptibility profiles of the isolated microorganisms. Rectal swabs and internal organs were obtained from 216 foals (89 diarrheic and 127 apparently healthy), aged 1 week to 1 year old, reared in Arabian horse farms in Great Cairo, Egypt during a period extended from March 2022 to December 2022. Conventional bacteriological examination was performed using selective media persuaded by routine and advanced biochemical tests. The isolation displayed 648 bacterial isolates; 452 (68.6%) were Gram-negative with the mixed isolation representing about 28%. Escherichia coli constituted the most prevalent; 110 / 452 (24.34%); 65 in apparently healthy foals and 45 among diarrheic ones. The second was Klebsiella pneumoniae (72, 15.92%) at which 50, (15.67%) were found to expose the highest causative agent recovered from diarrheic foals. Imipenem, quinolones, and trimethoprim/sulfamethoxazole were the most effective versus Gram-negative species isolated from diarrheic foals while ampicillin and tetracycline were of no effect. The phenotypic antibiotic susceptibility test revealed a picture of multidrug resistance (MDR) as 111 isolates (28.71%) showed resistance to three or more antibiotics belonging to different groups. The results demonstrated that Klebsiella pneumonia was the highest MDR species (54.16%) followed by Pseudomonas aeruginosa, Salmonella enterica, and Escherichia coli isolates by 43.9, 32.1 and 30.9 % respectively. In conclusion, Gram-negative bacteria constituted the major causative agents of diarrhea in the Arabian foals. The most effective antibacterial drugs were imipenem, quinolones, and trimethoprim/ sulfamethoxazole. The issue of the existence of multidrug resistance isolates should be considered for proper therapy of foal diarrhea
Risk assessment of atmospheric and liquid discharges of radionuclides on humans, marine biota and terrestrial wildlife
Prevalence of antibiotic resistant mastitis pathogens in dairy cows in Egypt and potential biological control agents produced from plant endophytic actinobacteria
The global, regional, and national burden of adult lip, oral, and pharyngeal cancer in 204 countries and territories : a systematic analysis for the global burden of disease study 2019
Abstract
Importance: Lip, oral, and pharyngeal cancers are important contributors to cancer burden worldwide, and a comprehensive evaluation of their burden globally, regionally, and nationally is crucial for effective policy planning.
Objective: To analyze the total and risk-attributable burden of lip and oral cavity cancer (LOC) and other pharyngeal cancer (OPC) for 204 countries and territories and by Socio-demographic Index (SDI) using 2019 Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study estimates.
Evidence review: The incidence, mortality, and disability-adjusted life years (DALYs) due to LOC and OPC from 1990 to 2019 were estimated using GBD 2019 methods. The GBD 2019 comparative risk assessment framework was used to estimate the proportion of deaths and DALYs for LOC and OPC attributable to smoking, tobacco, and alcohol consumption in 2019.
Findings: In 2019, 370 000 (95% uncertainty interval [UI], 338 000‐401 000) cases and 199 000 (95% UI, 181 000-217 000) deaths for LOC and 167 000 (95% UI, 153 000‐180 000) cases and 114 000 (95% UI, 103 000‐126 000) deaths for OPC were estimated to occur globally, contributing 5.5 million (95% UI, 5.0‐6.0 million) and 3.2 million (95% UI, 2.9‐3.6 million) DALYs, respectively. From 1990 to 2019, low-middle and low SDI regions consistently showed the highest age-standardized mortality rates due to LOC and OPC, while the high SDI strata exhibited age-standardized incidence rates decreasing for LOC and increasing for OPC. Globally in 2019, smoking had the greatest contribution to risk-attributable OPC deaths for both sexes (55.8% [95% UI, 49.2%‐62.0%] of all OPC deaths in male individuals and 17.4% [95% UI, 13.8%‐21.2%] of all OPC deaths in female individuals). Smoking and alcohol both contributed to substantial LOC deaths globally among male individuals (42.3% [95% UI, 35.2%‐48.6%] and 40.2% [95% UI, 33.3%‐46.8%] of all risk-attributable cancer deaths, respectively), while chewing tobacco contributed to the greatest attributable LOC deaths among female individuals (27.6% [95% UI, 21.5%‐33.8%]), driven by high risk-attributable burden in South and Southeast Asia.
Conclusions and relevance: In this systematic analysis, disparities in LOC and OPC burden existed across the SDI spectrum, and a considerable percentage of burden was attributable to tobacco and alcohol use. These estimates can contribute to an understanding of the distribution and disparities in LOC and OPC burden globally and support cancer control planning efforts
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients with Psoriasis
Importance: A clear dosing regimen for methotrexate in psoriasis is lacking, and this might lead to a suboptimal treatment. Because methotrexate is affordable and globally available, a uniform dosing regimen could potentially optimize the treatment of patients with psoriasis worldwide. Objective: To reach international consensus among psoriasis experts on a uniform dosing regimen for treatment with methotrexate in adult and pediatric patients with psoriasis and identify potential future research topics. Design, Setting, and Participants: Between September 2020 and March 2021, a survey study with a modified eDelphi procedure that was developed and distributed by the Amsterdam University Medical Center and completed by 180 participants worldwide (55 [30.6%] resided in non-Western countries) was conducted in 3 rounds. The proposals on which no consensus was reached were discussed in a conference meeting (June 2021). Participants voted on 21 proposals with a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree) and were recruited through the Skin Inflammation and Psoriasis International Network and European Academy of Dermatology and Venereology in June 2020. Apart from being a dermatologist/dermatology resident, there were no specific criteria for participation in the survey. The participants worked mainly at a university hospital (97 [53.9%]) and were experienced in treating patients with psoriasis with methotrexate (163 [91.6%] had more than 10 years of experience). Main Outcomes and Measures: In a survey with eDelphi procedure, we tried to reach consensus on 21 proposals. Consensus was defined as less than 15% voting disagree (1-3). For the consensus meeting, consensus was defined as less than 30% voting disagree. Results: Of 251 participants, 180 (71.7%) completed all 3 survey rounds, and 58 participants (23.1%) joined the conference meeting. Consensus was achieved on 11 proposals in round 1, 3 proposals in round 2, and 2 proposals in round 3. In the consensus meeting, consensus was achieved on 4 proposals. More research is needed, especially for the proposals on folic acid and the dosing of methotrexate for treating subpopulations such as children and vulnerable patients. Conclusions and Relevance: In this eDelphi consensus study, consensus was reached on 20 of 21 proposals involving methotrexate dosing in patients with psoriasis. This consensus may potentially be used to harmonize the treatment with methotrexate in patients with psoriasis.